Archive for June 10th, 2011

MITI promising Blinatumomab data. PARD to hold another reverse split vote

Jun 10, 2011 No Comments by

Micromet (Nasdaq: MITI) released promising interim results from its Phase 2 single-arm trial of Blinatumomab for acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy. Data showed that 75% of patients (9 of 12) achieved a complete remission (CR) or CR with partial recovery of blood counts (CRh) following treatment with blinatumomab. […]

Daily News Read more